|
AU2015367378A1
(en)
|
2014-12-17 |
2017-06-15 |
Proqr Therapeutics Ii B.V. |
Targeted RNA editing
|
|
EP3475424A1
(en)
|
2016-06-22 |
2019-05-01 |
ProQR Therapeutics II B.V. |
Single-stranded rna-editing oligonucleotides
|
|
WO2018041973A1
(en)
|
2016-09-01 |
2018-03-08 |
Proqr Therapeutics Ii B.V. |
Chemically modified single-stranded rna-editing oligonucleotides
|
|
GB201808146D0
(en)
|
2018-05-18 |
2018-07-11 |
Proqr Therapeutics Ii Bv |
Stereospecific Linkages in RNA Editing Oligonucleotides
|
|
AU2020313143B2
(en)
*
|
2019-07-12 |
2024-04-04 |
Peking University |
Targeted RNA editing by leveraging endogenous adar using engineered RNAs
|
|
CA3159799A1
(en)
*
|
2019-12-02 |
2021-06-10 |
Prashant MALI |
Engineering circular guide rnas
|
|
US11827880B2
(en)
|
2019-12-02 |
2023-11-28 |
Shape Therapeutics Inc. |
Therapeutic editing
|
|
WO2022150773A2
(en)
*
|
2021-01-11 |
2022-07-14 |
The Regents Of The University Of California |
Ribozyme-activated rna constructs and uses thereof
|
|
JP2024504608A
(ja)
*
|
2021-01-12 |
2024-02-01 |
北京大学 |
遺伝子操作rnaを使用した内因性adarの活用による標的化rnaの編集
|
|
EP4355902A4
(en)
*
|
2021-06-17 |
2025-04-30 |
The Board Of Trustees Of The University Of Illinois |
Crispr cascade
|
|
EP4479535A1
(en)
|
2022-02-14 |
2024-12-25 |
ProQR Therapeutics II B.V. |
Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
|
|
EP4555086A1
(en)
|
2022-07-15 |
2025-05-21 |
ProQR Therapeutics II B.V. |
Oligonucleotides for adar-mediated rna editing and use thereof
|
|
EP4555085A1
(en)
|
2022-07-15 |
2025-05-21 |
ProQR Therapeutics II B.V. |
Chemically modified oligonucleotides for adar-mediated rna editing
|
|
GB202215614D0
(en)
|
2022-10-21 |
2022-12-07 |
Proqr Therapeutics Ii Bv |
Heteroduplex rna editing oligonucleotide complexes
|
|
KR20250113455A
(ko)
|
2022-11-24 |
2025-07-25 |
프로큐알 테라퓨틱스 Ⅱ 비.브이. |
유전성 hfe-혈색소침착증의 치료를 위한 안티센스 올리고뉴클레오티드
|
|
GB202218090D0
(en)
|
2022-12-01 |
2023-01-18 |
Proqr Therapeutics Ii Bv |
Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
|
|
WO2024121373A1
(en)
|
2022-12-09 |
2024-06-13 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of cardiovascular disease
|
|
GB202300865D0
(en)
|
2023-01-20 |
2023-03-08 |
Proqr Therapeutics Ii Bv |
Delivery of oligonucleotides
|
|
WO2024175550A1
(en)
|
2023-02-20 |
2024-08-29 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease
|
|
JP2026510408A
(ja)
|
2023-03-24 |
2026-04-02 |
プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ |
神経障害の処置のためのアンチセンスオリゴヌクレオチド
|
|
GB202304363D0
(en)
|
2023-03-24 |
2023-05-10 |
Proqr Therapeutics Ii Bv |
Chemically modified antisense oligonucleotides for use in RNA editing
|
|
EP4688143A1
(en)
|
2023-03-27 |
2026-02-11 |
ProQR Therapeutics II B.V. |
Antisense oligonucleotides for the treatment of liver disease
|
|
CN118995701A
(zh)
*
|
2023-05-17 |
2024-11-22 |
中国科学院遗传与发育生物学研究所 |
基于环状rna的引导编辑系统
|
|
WO2024256620A1
(en)
|
2023-06-16 |
2024-12-19 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of neurodegenerative disease
|
|
EP4774393A1
(en)
|
2023-09-07 |
2026-07-15 |
ProQR Therapeutics II B.V. |
Antisense oligonucleotides for the treatment of metabolic disorders
|
|
AU2024379264A1
(en)
|
2023-11-16 |
2026-05-14 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of classic galactosemia
|
|
AU2024402199A1
(en)
|
2023-12-20 |
2026-07-16 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of huntington's disease
|
|
WO2025137637A2
(en)
*
|
2023-12-21 |
2025-06-26 |
Shape Therapeutics Inc. |
Wobble base pairs for improving specificity of rna editing
|
|
WO2025207635A1
(en)
*
|
2024-03-25 |
2025-10-02 |
University Of Wyoming |
Compositions and methods for stabilizing a biological material or biologically-derived material
|
|
GB202404661D0
(en)
|
2024-04-02 |
2024-05-15 |
Proqr Therapeutics Ii Bv |
Antisense oligoncleotides for the treatment of liver disease
|
|
WO2025224230A1
(en)
|
2024-04-25 |
2025-10-30 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of fatty liver disease
|
|
GB202410081D0
(en)
|
2024-07-11 |
2024-08-28 |
Proqr Therapeutics Ii Bv |
Antisense oligonucleotides for the treatment of cardiovascular disease
|
|
WO2026022136A1
(en)
|
2024-07-23 |
2026-01-29 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of metabolic disorders
|
|
WO2026060374A2
(en)
|
2024-09-16 |
2026-03-19 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of neurological disorders
|
|
WO2026068781A1
(en)
|
2024-09-30 |
2026-04-02 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of liver disease
|
|
WO2026093339A1
(en)
|
2024-10-29 |
2026-05-07 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of peroxisome biogenesis disorders in the zellweger spectrum (pbd-zsd)
|
|
WO2026136663A1
(en)
|
2024-12-18 |
2026-06-25 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of neurodegenerative disease
|